Breast Cancer Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (03/24/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Breast Cancer

Added the Risk Factors module.

Added Protective Factors as a new subsection.

Early/Localized/Operable Breast Cancer

Added text to state that a randomized, phase III, double-blind study has demonstrated noninferiority for the duration of severe neutropenia of biosimilar filgrastim compared with the U.S.-licensed product (cited Blackwell et al. as reference 98 and level of evidence 1iDiv).

Added text to state that similar results were noted in a larger, multicenter, randomized study led by the Hellenic Oncology Research Group (cited Mavroudis et al. as reference 122 and level of evidence 1iiA).

Metastatic Breast Cancer

Revised text to state that palbociclib is an orally available CDK4/6 inhibitor that has been shown in two trials to enhance the efficacy of endocrine therapy and has been approved by the U.S. Food and Drug Administration (FDA).

Added text to state that PALOMA-2, a phase III, double-blind trial, confirmed the results of the PALOMA-1 trial by comparing placebo plus letrozole with palbociclib plus letrozole as initial therapy for estrogen receptor (ER)–positive postmenopausal patients with advanced disease. Added statistical information to show that progression-free survival (PFS), the primary endpoint, was met; no overall survival (OS) data are available; and adverse events in the two groups were included (cited Finn et al. as reference 33 and level of evidence 1iDiii).

Added text to state that ribociclib was also tested in the first-line setting for postmenopausal patients with ER–positive and HER2–negative recurrent or metastatic breast cancer in a phase III, placebo-controlled trial in which patients received ribociclib plus letrozole or placebo plus letrozole. Added statistical information to show that PFS, the primary endpoint, was met; the median PFS data were provided; no OS data are available; and graded data about specific adverse events in the two groups were included (cited Hortobagyi et al. as reference 36 and level of evidence 1iDiii).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Ductal Carcinoma In Situ

Next section >
About This PDQ Summary